56 related articles for article (PubMed ID: 18383843)
1. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts.
Nakahira S; Nakamori S; Tsujie M; Takeda S; Sugimoto K; Takahashi Y; Okami J; Marubashi S; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Anticancer Res; 2008; 28(1A):179-86. PubMed ID: 18383843
[TBL] [Abstract][Full Text] [Related]
2. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM
Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758
[TBL] [Abstract][Full Text] [Related]
3. S-1 in the treatment of pancreatic cancer.
Sudo K; Nakamura K; Yamaguchi T
World J Gastroenterol; 2014 Nov; 20(41):15110-8. PubMed ID: 25386059
[TBL] [Abstract][Full Text] [Related]
4. Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Prudner BC; Rathore R; Robinson AM; Godec A; Chang SF; Hawkins WG; Hirbe AC; Van Tine BA
Clin Cancer Res; 2019 Aug; 25(16):5122-5134. PubMed ID: 31113844
[TBL] [Abstract][Full Text] [Related]
5. Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.
Tu MJ; Ho PY; Zhang QY; Jian C; Qiu JX; Kim EJ; Bold RJ; Gonzalez FJ; Bi H; Yu AM
Cancer Lett; 2019 Feb; 442():82-90. PubMed ID: 30389433
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
Courtin A; Richards FM; Bapiro TE; Bramhall JL; Neesse A; Cook N; Krippendorff BF; Tuveson DA; Jodrell DI
PLoS One; 2013; 8(6):e67330. PubMed ID: 23840665
[TBL] [Abstract][Full Text] [Related]
7. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial.
Okamura Y; Boku N; Ghaneh P; Greenhalf W; Yasukawa S; Narimatsu H; Fukutomi A; Konishi M; Morinaga S; Toyama H; Maeda A; Shimizu Y; Nakamori S; Sata N; Yamakita K; Takahashi A; Takayama W; Yamaguchi R; Tomikawa M; Yanagisawa A; Neoptolemos JP; Uesaka K
Cancer Rep (Hoboken); 2022 May; 5(5):e1507. PubMed ID: 34327872
[TBL] [Abstract][Full Text] [Related]
8. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.
Takahara A; Koido S; Ito M; Nagasaki E; Sagawa Y; Iwamoto T; Komita H; Ochi T; Fujiwara H; Yasukawa M; Mineno J; Shiku H; Nishida S; Sugiyama H; Tajiri H; Homma S
Cancer Immunol Immunother; 2011 Sep; 60(9):1289-97. PubMed ID: 21607557
[TBL] [Abstract][Full Text] [Related]
10. CQ sensitizes human pancreatic cancer cells to gemcitabine through the lysosomal apoptotic pathway via reactive oxygen species.
Fu Z; Cheng X; Kuang J; Feng H; Chen L; Liang J; Shen X; Yuen S; Peng C; Shen B; Jin Z; Qiu W
Mol Oncol; 2018 Apr; 12(4):529-544. PubMed ID: 29453806
[TBL] [Abstract][Full Text] [Related]
11. An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.
Nishimura G; Yanoma S; Satake K; Ikeda Y; Taguchi T; Nakamura Y; Hirose F; Tsukuda M
Jpn J Cancer Res; 2000 Nov; 91(11):1199-203. PubMed ID: 11092987
[TBL] [Abstract][Full Text] [Related]
12. Co-Delivery of Gemcitabine and Honokiol by Lipid Bilayer-Coated Mesoporous Silica Nanoparticles Enhances Pancreatic Cancer Therapy via Targeting Depletion of Tumor Stroma.
Liu D; Wang L; Li H; Li D; Zhou J; Wang J; Zhang Q; Cai D
Molecules; 2024 Jan; 29(3):. PubMed ID: 38338418
[TBL] [Abstract][Full Text] [Related]
13. An integrated PK/PD model investigating the impact of tumor size and systemic safety on animal survival in SW1990 pancreatic cancer xenograft.
Yao QY; Zhou J; Yao Y; Xue JS; Guo YC; Jian WZ; Zhang RW; Qiu XY; Zhou TY
Acta Pharmacol Sin; 2023 Feb; 44(2):465-474. PubMed ID: 35953645
[TBL] [Abstract][Full Text] [Related]
14. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA.
Aughton K; Elander NO; Evans A; Jackson R; Campbell F; Costello E; Halloran CM; Mackey JR; Scarfe AG; Valle JW; Carter R; Cunningham D; Tebbutt NC; Goldstein D; Shannon J; Glimelius B; Hackert T; Charnley RM; Anthoney A; Lerch MM; Mayerle J; Palmer DH; Büchler MW; Ghaneh P; Neoptolemos JP; Greenhalf W
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830914
[TBL] [Abstract][Full Text] [Related]
15. Highly Reproducible Quantitative Proteomics Analysis of Pancreatic Cancer Cells Reveals Proteome-Level Effects of a Novel Combination Drug Therapy That Induces Cancer Cell Death via Metabolic Remodeling and Activation of the Extrinsic Apoptosis Pathway.
Rasam S; Lin Q; Shen S; Straubinger RM; Qu J
J Proteome Res; 2023 Dec; 22(12):3780-3792. PubMed ID: 37906173
[TBL] [Abstract][Full Text] [Related]
16. A Cathepsin B-Sensitive Gemcitabine Prodrug for Enhanced Pancreatic Cancer Therapy.
Wang S; Cen D; Zhang C
J Pharm Sci; 2024 Mar; ():. PubMed ID: 38555998
[TBL] [Abstract][Full Text] [Related]
17. Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models.
Inkoom A; Ndemazie N; Affram K; Smith T; Zhu X; Underwood P; Krishnan S; Ofori E; Han B; Trevino J; Agyare E
Int J Pharm X; 2020 Dec; 2():100056. PubMed ID: 33015617
[TBL] [Abstract][Full Text] [Related]
18. Histidine Enhances the Anticancer Effect of Gemcitabine against Pancreatic Cancer via Disruption of Amino Acid Homeostasis and Oxidant-Antioxidant Balance.
Kumar N; Rachagani S; Natarajan G; Crook A; Gopal T; Rajamanickam V; Kaushal JB; Nagabhishek SN; Powers R; Batra SK; Saraswathi V
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174059
[TBL] [Abstract][Full Text] [Related]
19. Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-vitro evaluation against pancreatic cancer.
Frimpong E; Bulusu R; Okoro J; Inkoom A; Ndemazie N; Rogers S; Zhu X; Han B; Agyare E
Eur J Pharm Sci; 2024 May; 196():106754. PubMed ID: 38554983
[TBL] [Abstract][Full Text] [Related]
20. Bitter melon juice activates cellular energy sensor AMP-activated protein kinase causing apoptotic death of human pancreatic carcinoma cells.
Kaur M; Deep G; Jain AK; Raina K; Agarwal C; Wempe MF; Agarwal R
Carcinogenesis; 2013 Jul; 34(7):1585-92. PubMed ID: 23475945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
